Loading
Nearly a quarter of 214 Bahamian women with breast cancer, chosen without regard to age or family history, carried one of six BRCA1 founder mutations, the highest national prevalence recorded.
214 Bahamian women with invasive breast cancer, unselected for age or family history, were screened for six BRCA1 mutations previously reported in Bahamian cancer families. A mutation was identified in 49 (23%); frequency was 33% in women diagnosed before 50, 41% with a first-degree relative with breast or ovarian cancer and 58% with bilateral disease. About 23% of unselected breast cancers in the Bahamas are attributable to a BRCA1 founder mutation.
Founder-mutation screening of every breast cancer patient is justified in the Bahamas, and the finding explains part of the early-onset, BRCA1-driven triple-negative burden across Afro-Caribbean populations.
Shares Breast cancer research and treatment, Germline BRCA mutation (gBRCA), BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
Shares Breast cancer research and treatment, Germline BRCA mutation (gBRCA), BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
Shares Germline BRCA mutation (gBRCA), BRCA1 / BRCA2 (HRD), Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares Germline BRCA mutation (gBRCA), BRCA1 / BRCA2 (HRD), Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares Germline BRCA mutation (gBRCA), BRCA1 / BRCA2 (HRD), Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares Breast cancer research and treatment, Triple-negative breast cancer (TNBC).
Shares Breast cancer research and treatment, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
Shares BRCA1 / BRCA2 (HRD), Breast cancer (all types), Triple-negative breast cancer (TNBC).